Medicine company Eli Lilly and Company (NYSE: LLY) and biopharmaceutical company Morphic Holding Inc (NASDAQ: MORF) on Monday announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical firm developing oral integrin therapies for serious chronic diseases.
Morphic's lead program, MORF-057, a selective oral small molecule inhibitor of α4β7 integrin, targets inflammatory bowel disease (IBD) and is undergoing Phase 2 studies in ulcerative colitis and Crohn's disease. Morphic also has a preclinical pipeline for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer.
Lilly will launch a tender offer to purchase all Morphic shares at USD57 per share in cash, totaling approximately USD3.2bn. This represents a 79.0% premium to the closing stock price on 5 July 2024. The transaction, approved by both companies' boards, is expected to close in Q3 2024, subject to customary conditions.
Lilly's financial results will reflect the acquisition as a business combination or asset acquisition per GAAP. Citi and Kirkland & Ellis LLP are advising Lilly, while Centerview Partners LLC, Evercore Group L.L.C. and Fenwick & West LLP are advising Morphic.
With nearly 150-year history of pioneering life-changing medicines, Lilly aims to improve patient outcomes and expand treatment options for IBD with this acquisition.
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lipella launches OLP Patient Registry to advance research
Talphera enrols first subject in NEPHRO CRRT study
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Cantargia reports positive CAN10 trial data
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development